Antiretroviral treatment switch strategies for lowering the costs of antiretroviral therapy in subjects with suppressed HIV-1 viremia in Spain

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 215-221

  Llibre, Josep M ^a,b   Cardona, Gloria ^a   Santos, José R ^b   Andreu, Angels ^a   Estrada, Josep O ^a   Ara, Jordi ^a   Bonafont, Xavier ^a   Clotet, Bonaventura ^a,b  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Lluita Contra la SIDA Foundation   (Spain)

Author keywords

Antiretroviral agents economics; Antiretroviral therapy highly active; Cost analysis; Health economics; Protease inhibitor monotherapy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTIRETROVIRUS AGENT; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE; ETRAVIRINE; FOSAMPRENAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; TENOFOVIR; TIPRANAVIR;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ECONOMIC EVALUATION; ECONOMIC RECESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; SPAIN; UNSPECIFIED SIDE EFFECT;

EID: 84878294286     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S43662     Document Type: Article

References (25)

1. Kentikelenis A, Karanikolos M, Papanicolas I, Basu S, McKee M, Stuckler D. Health effects of financial crisis: omens of a Greek tragedy. Lancet. 2011;378(9801):1457-1458.
2. Stuckler D, Basu S, Suhrcke M, Coutts A, McKee M. The public health effect of economic crises and alternative policy responses in Europe: an empirical analysis. Lancet. 2009;374(9686):315-323.
3. Farmaindustria. [press release]. Madrid, Spain: Farmaindustria; January 26, 2012. Available from: http://www.farmaindustria.es/Prensa_Farma/NotasDePrensa/FARMA_113933?idDoc=FARMA_113933. Accessed August 30, 2012. Spanish.
4. Sahuquillo MR. El gasto farmacéutico hospitalario crece un 55% en cuatro años. [The hospital pharmaceutical budget increases 55% in 4 years]. El País. 2011. Available from: http://elpais.com/diario/2011/11/10/sociedad/1320879603_850215.html. Accessed August 30, 2012. Spanish.
5. Hospital pharmacy. Ambulatory Spending Products in Spain, 2007. Spanish Working Group for the Analysis of Health Investments; Available from: http://www.msps.es/estadEstudios/estadisticas/sisInfSanSNS/pdf/grupodeTrabajoSanitario2007.pdf. Accessed July 27, 2007;20:540-552. Spanish.
6. Hospital pharmacy. Ambulatory Spending Products in Spain, 2006. Spanish Working Group for the Analysis of Health Investments; 2007. Available from: http://www.msps.es/estadEstudios/estadisticas/sisInfSanSNS/pdf/grupodeTrabajoSanitario2007.pdf. Accessed July 27, 2012:540-552. Spanish.
7. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-128.
8. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11-19.
9. Mandalia S, Mandalia R, Lo G, et al. Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS One. 2010;5(12):e15677.
10. Generalitat de Catalunya [homepage on the Internet]. Action plan for the sustainability of the Health System 2011; 2011. Available from: http://www10.gencat.cat/gencat/AppJava/cat/actualitat2/2011/10302plademesuresurgentsperalasostenibilitatdelsistemasanitari2011.jsp. Accessed July 27, 2012. Spanish.
11. Gazzard B, Moecklinghoff C, Hill A. New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom. Clinicoecon Outcomes Res. 2012;4: 193-200.
12. Executive summary. Consensus document of GESIDA and SPNS (Spanish Secretariat for the National Plan on AIDS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (Jan 2012). Enferm Infecc Microbiol Clin. 2012;30(6):315-324.
13. European AIDS Clinical Society [Homepage on the Internet]. Guidelines version 6.0 - Oct 2011. Available from: http://www.europeanaidsclinicalsociety.org/. Accessed July 28, 2012.
14. Pasquau J, Gostkorzewicz J, Ledesma F, Anceau A, Hill A, Moecklinghoff C. Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain. Appl Health Econ Health Policy. 2012;10(2):139-141.
15. Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy. 2011;9(4):217-223.
16. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available form: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed September 4, 2012:1-239.
17. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402.
18. British HIV Association [Homepage on the Internet]. BHIVA guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. Available from: http://www.bhiva.org/. Accessed September 4, 2012.
19. Beck EJ, Mandalia S, Sangha R, et al. The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008. PLoS One. 2011;6(12):e27830.
20. Nosyk B, Montaner JS. The evolving landscape of the economics of HIV treatment and prevention. PLoS Med. 2012;9(2):e1001174.
21. Sloan CE, Champenois K, Choisy P, et al. Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults. AIDS. 2012;26(1):45-56.
22. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6): 493-505.
23. Cohen MS, Muessig KE, Smith MK, Powers KA, Kashuba AD. Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS. 2012;26(13):1585-1598.
24. Callahan D. Cost control - time to get serious. N Engl J Med. 2009; 361(7):e10.
25. Gonzalo T, Garcia GM, Muñoz-Fernández MA. Socio-economic impact of antiretroviral treatment in HIV patients. An economic review of cost savings after introduction of HAART. AIDS Rev. 2009;11(2):79-90.